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ABSTRACT: 
Background/aim: Cytogenetic profile of posterior uveal melanoma (mainly 
monosomy 3) is actually considered the most specific prognostic factor for uveal 
melanoma patients. Nevertheless, there is still no consensus on which cytogenetic 
analysis should be used, and there is still no long-term data about the safety of 
sampling procedure. The aims of this study were to evaluate (i) long-term safety 
and efficacy of in-vivo 25-gauge transcleral Fine Needle Aspiration Biopsy (FNAB) 
and (ii) predictive value of Fluorescent In-situ Hybridization (FISH) vs Multiplex 
Ligation-dependent Probe Amplification (MLPA) analysis for cytogenetic testing of 
posterior uveal melanoma. 
 
Methods: One hundred thirty-nine consecutive patients affected by posterior uveal 
melanoma with tumour thickness > 3mm underwent in-vivo 25-G transcleral FNAB 
(through the tumor base) just before applying the I-125 active plaque. A double 
pass sampling was performed. Sampled material underwent both FISH 
(chromosome 3 and 6) and MLPA analysis using standard procedures. Follow-up 
examination, including A/B-Scan eye and orbit ultrasonography, was performed 
after 1 month and every 6 months thereafter. Follow-up was longer than 24 months. 
 
Result: Follow-up was 54±16 months (range, 24-84 months). FNAB yielded 
sufficient material for FISH analysis in 117 cases (84.2%). Fifty-six cases had 
monosomy 3 (47.9%). No clinically relevant monosomy 3 heterogeneity was 
detected (double pass sampling). Chromosome 6 co-detection using FISH was 
performed in forty-four patients. Monosomy 3 and +6p resulted mutually exclusive in 
40 cases (90.9%). Univariate Cox analysis showed metastatic disease to be 
strongly associated with monosomy 3 (p=0.005). No misclassification occurred in 
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low risk patients having both disomy 3 and +6p. MLPA was performed in twenty-
four patients revealing monosomy 3 in thirteen cases (54%) (vs twelve cases 
classified by FISH) and a 3p14-q29 deletion in one case (4%) (classified as 
monosomy 3 by FISH). Considering this sub-group of twenty-four patients having 
both FISH and MLPA, nine patients (41%) developed metastatic disease during 
follow-up, including the case showing monosomy 3 only by MLPA. Patient with 
partial chromosome 3 deletion by MLPA is still alive without metastases. Due to 
FNAB procedure, tree patients developed transient, localized and self-limited 
subretinal haemorrhages after FNAB. Neither other short- and long-term 
complications nor extrascleral extensions were documented during follow up. 
 
Conclusion: The use of 25-G transcleral FNAB appears a long-term safe and 
effective procedure for in-vivo cytogenetic testing of posterior uveal melanoma. 
Combined analysis of both arms of uveal melanoma bifurcated pathway (-3 and 
+6p) increase predictive value of FISH technique. MLPA allows obtaining more 
information than standard FISH in uveal melanoma prognostication. The biological 
and prognostic value of partial chromosome 3 deletion, as well as others subtle 
chromosomes alterations or complex MLPA results, remains unclear.  
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RIASSUNTO: 
Introduzione/scopo: il profilo citogenetico del melanoma uveale (in particolare la 
monosomia 3) è attualmente considerato il fattore prognostico più specifico per il 
rischio metastatico nei pazienti affetti da melanoma uveale. Ciononostante, non c’è 
ancora accordo su quale analisi citogenetica debba essere preferita. Inoltre, 
mancano dati a lungo termine sulla sicurezza della procedura di prelievo. Gli 
obiettivi di questo studio sono (i) valutare la sicurezza a lungo termine e l’efficacia 
del prelievo transclerale in-vivo mediante citoaspirazione con ago sottile (FNAB) da 
25-gauge e (ii) valutare il valore predittivo del metodo Fluorescent In-situ 
Hybridization (FISH) vs il metodo Multiplex Ligation-dependent Probe Amplification 
(MLPA) per l’analisi citogenetica del melanoma coroideale 
 
Materiali e metodi: Centotrentanove pazienti, consecutivamente reclutati poiché 
affetti da melanoma uveale con spessore tumorale >3 mm, sono stati sottoposti a 
prelievo in-vivo mediante FNAB transclerale con ago da 25-gauge (attraverso la 
base del tumore), immediatamente prima di suturare la placca radiante di I-125. Il 
prelievo è stato ripetuto due volte. Il materiale prelevato è stato sottoposto a FISH 
(cromosomi 3 e 6) e MLPA usando le procedure standard. Il protocollo di follow-up, 
incluso l’ecografia A-B scan del bulbo oculare e dell’orbita, prevedeva una visita al 
primo mese dopo l’intervento e, in seguito, ogni 6 mesi. Il follow-up minimo è stato 
superiore a 24 mesi. 
 
Risultati: Il follow-up medio è stato di 54±16 mesi (range, 24-84 mesi), La 
procedure FNAB ha fornito sufficiente materiale per l’analisi FISH in 117 casi 
(84.2%). Cinquantasei casi sono risultati monosomici per il cromosoma 3 (47.9%). 
Non è stata rilevata eterogeneicità clinicamente rilevante della monosomia 3 
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all’interno dello stesso tumore (doppio prelievo). La co-analisi del cromosoma 6 è 
stata effettuata in quarantaquattro pazienti. La monosomia del cromosoma 3 e il 
+6p sono risultate mutualmente escludenti in 40 casi (90.9%). Lo sviluppo di 
malattia metastatica è stato correlato in modo significativo con la presenza della 
monosomia 3 (p=0.005) (Univariate Cox analysis). Nessun paziente a basso 
rischio, caratterizzato sia da disomia 3 che da +6p ha sviluppato malattia 
metastatica. L’analisi MLPA è stata eseguita in ventiquattro pazienti, rilevando la 
presenza di monosomia 3 in tredici casi (54%) (vs dodici casi classificati 
monosomici dalla FISH) e la presenza di una delezione 3p14-q29in un caso (4%) 
(classificato come monosomico dalla FISH). Considerando questo sottogruppo 
avente sia il dato FISH che MLPA, nove pazienti (41%) hanno sviluppato malattia 
metastatica, compreso il caso classificato come monosomico solo dall’analisi 
MLPA. Il paziente con delezione parziale del cromosoma 3 è ancora in vita senza 
segni di malattia metastatica in atto. Tre pazienti hanno presentato una limitata 
emorragia vitreale spontaneamente regredita in pochi giorni in seguito al prelievo 
FNAB. Nessun’altra complicanza a breve o lungo termine, compreso lo sviluppo di 
estensione extrasclerale della neoplasia in sede di prelievo, è stata rilevata durante 
il follow-up. 
 
Conclusioni: L’uso del prelievo FNAB transclerale mediante ago da 25-gauge è 
una procedura sicura ed efficace per l’analisi citogenetica del melanoma uveale. 
L’analisi combinata di entrambe le vie patogenetiche (-3 e +6p) innalza il valore 
predittivo della tecnica FISH. La tecnica MLPA consente di ottenere maggiori 
informazioni rispetto alla tecnica FISH. Purtroppo però, il valore biologico e 
prognostico di delezioni parziali del cromosoma 3 o di altre alterazioni 
cromosomiche parziali rimane sconosciuto. 
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INTRODUCTION 
 
Posterior uveal melanoma (UM) is the most common primary intraocular malignant 
tumor in adults, with an annual incidence of five to seven cases per million 
population (FIG1).1 Although the goal of treating the tumor and preserving the eye is 
achieved in most cases (>90% using eye preserving radiation treatments), overall 
mortality remains high (about 50%). 2 Nevertheless, less than 2% of affected 
patients have clinically detectable metastasis at presentation.2 The preferred spread 
of UM is haematogenous, and the liver is often the first and prevalent site of 
metastatic disease (FIG2).3 However, UM can metastasize to any organ and other 
common sites include the lungs, bones, soft tissues, gastro-enteric tract, ovaries, 
kidneys and central nervous system (CNS).3 The reported median life expectancy of 
patients affected by metastatic UM ranges from 3.6 to 15 months, with worse 
survival in larger series and better survival in the smaller ones.4 Site of metastases, 
number of metastatic sites, percentage of liver substitution, diameter of liver 
metastases, presence of symptoms, alteration of liver function tests, especially 
alkaline phosphatase (ALP) and lactic dehydrogenase (LDH), older age, male sex, 
and a shorter metastasis-free interval have been associated with a poorer 
prognosis. 3 Before the introduction of eye preserving treatment based on irradiation 
of the tumor, eye enucleation was the standard treatment for UM patients, and 
histopathologyc characteristics of the tumor were considered the most reliable 
prognostic factor.5, 6 Because most UM are currently treated with conservative 
treatment, no material is available for cytologic or histologic evaluation. 6 Therefore, 
most treated patients receive prognostic information based only on clinical 
characteristics of the tumor (largest basal diameter, thickness, location). 2, 6 
Unfortunately, these parameters are unable to accurately characterize patients’ 
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prognosis. 2, 5-6 It has been recently demonstrated that a cytogenetic characteristic 
of UM, namely monosomy 3 (-3), is highly predictive of metastatic disease. 2, 5-6 This 
parameter seems a better predictor of metastasis than any other clinical and/or 
histopathologic parameter previously reported. 7 Some retrospective analyses of 
cytogenetic data have hypothesized that two cytogenetic pathways of clonal 
evolution exist in UM: one starts with the loss of an entire chromosome 3 and 
continues with gains of 8q; the second pathway starts with gain of 6p (FIG 3). 8-11 
Long-term studies have shown that about 70% of patients with monosomy 3 in the 
primary tumor died from metastases within 4 years after the initial diagnosis, 
whereas tumors with normal chromosome 3 status (disomy 3) rarely gave rise to 
metastatic disease (FIG 4). 2, 5-6, 8-11 Therefore, monosomy 3 is considered a highly 
specific marker for poor prognosis in UM. 2, 5-6, 8-11 Monosomy 3 has been initially 
detected only in enucleated eyes or histologic specimens from resected tumors. 2, 5-
6 Therefore, patients treated with irradiation (90% of UM population) were excluded 
from this prognostic information. Considering that accurate identification of patients 
at high risk of developing metastatic disease may be relevant for clinical 
management of any UM patients, few years ago, our team have first described the 
in-vivo sampling technique for cytogenetic testing of UM conservatively treated. 2, 5 
After our first report, many centres started performing tumor biopsy for UM 
prognostication, using different sampling techniques and different 
cytogenetic/molecular biology analysis. 11 Moreover, there is still no consensus on 
which sampling technique and cytogenetic analysis should be used, and there is still 
no agreement on the overall interpretation of the interrelationships between 
chromosomes changes (mainly chromosome 6 and 8) and their prognostic values. 
11 Moreover, there is still no long-term data about the safety of different sampling 
procedure. 
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AIM 
 
The aims of this study were to evaluate (i) long-term safety and efficacy of in-vivo 
25-gauge transcleral Fine Needle Aspiration Biopsy (FNAB) and (ii) predictive value 
of Fluorescent In-situ Hybridization (FISH) vs Multiplex Ligation-dependent Probe 
Amplification (MLPA) analysis for cytogenetic testing of posterior UM. 
 
MATERIALS AND METHODS 
 
This study complied with the tenets of the Declaration of Helsinki, and was 
approved by the IRB of our institution. Patients were recruited from those referred to 
the Ophthalmic Oncology Unit of the Department of Ophthalmology, University of 
Padova, Padova, Italy, between September 2001 and November 2009. Each patient 
underwent full preoperative ophthalmic and systemic examination. The 
ophthalmoscopic aspects of the tumors were documented using fundus 
photography (FIG1). UM dimensions were also documented using A- and B-scan 
ultrasonography. Liver enzymes and liver ultrasonography were used to evaluate 
the presence of metastatic disease at baseline. Eligible patients were affected by 
primary UM with tumour thickness > 3mm, and were free of metastasis and other 
cancers at enrolment, free of melanoma extrascleral extension, 21 years or older, 
and free from other life-threatening coexisting systemic diseases. Informed consent 
was obtained after explanation of the nature of the disease and the possible 
implications of this study. All patients were scheduled for standard plaque 
brachytherapy with I125, under general anaesthesia. One hundred thirty-nine 
consecutive patients undergoing plaque radiotherapy, with follow-up longer than 24 
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months, were included in this study. 
Patients underwent an in-vivo intraocular FNAB during the procedure for radioactive 
plaque application, as previously described (Fig 5-8). 2, 6,11 Briefly, the cytologic 
sampling was made through the sclera, just before suturing the active I125 plaque 
over the tumor base. A standard FNAB procedure was performed using a 25-gauge 
blunt needle, 27 mm in length (Becton Dickinson, New York, NY, USA). A 200– 300 
µ pre-planned scleral incision was made, and the needle inserted into the tumor 
through the remaining sclera. A double-pass sampling was performed. The scleral 
incision was sutured with 7.0 Polyglactin suture, and the radioactive plaque 
immediately placed over the tumor base. Tumor specimens obtained by FNAB were 
collected in culture medium RPMI 1640 (Euroclone Life Science, Milano, Italy). 
Each patient was treated by Iodine-125 plaque brachytherapy following the 
American Brachytherapy Society recommendations for brachytherapy of UM (dose 
of 85-100 Gy at tumor apex, dose rate of 0.60–1.05 Gy/h). 12 Each patient 
underwent a 1-month follow-up examination, and every 6 months thereafter. Follow-
up examination included full ophthalmologic examination, fundus photography and 
A- and B-scan ultrasonography. Orbit nuclear magnetic resonance was used in 
selected cases basing on clinical and ultrasonography data. Liver enzymes analysis 
and liver ultrasonography were also performed every 6 months to check for 
metastatic diffusion. When the site of needle aspiration was detectable through slit 
lamp examination, this area underwent regular photographic follow-up. 
FISH for chromosome 3 was performed with a centromeric probe labeled with 
SpectrumOrange fluorocrome (Vysis-Abbott, Downers Grove, IL, USA), as 
previously described by our group (Fig 9-10). 2, 6 Briefly, after sedimentation, the 
material was enzymatically digested with collagenase II (Worthington, NJ. USA) 
1400 U/mL at 37 °C for 2 hours. Then the suspension was washed in RPMI 1640 
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and used to prepared cytospins. Slides were fixed with a cytologic fixative (Bio- Fix; 
Bio-Optica, Milano, Italy), and stored at –20 °C. FISH analysis was performed with a 
centromeric probe for chromosome 3 labeled with SpectrumOrange and 
centromeric probe for chromosome 10 labeled with SpectrumGreen (Abbott-Vysis, 
Downers Grove, IL, USA) following the manufacturer’s procedure. Slide and probe 
were codenatured in Hybrite‘ (Vysis) at 75 °C for 5’ and hybridized in a humid 
chamber overnight at 42 °C. Post-hybridization washes were made at 73 °C in 0.4 x 
SSC/0.3% NP-40 for 2’ and at room temperature in 2 x SSC/0, 1% NP-40 for 1’. 
Slides were air dried and mounted with a Vectashield‚ mounting medium with DAPI 
(Vector Laboratories, Burlingame). Microscope analysis was carried out with a 
fluorescent microscope (Zeiss Axioplan fluorescent microscope, Germany) 
equipped with a cooled charge-coupled device (CCD) camera (Hamamatsu, 
Hamamatsu-city, Japan) and appropriate single band and triple band filters. Images 
were analyzed using CRO- MOFISH software (Amplimedical, Assago-MI, Italy). At 
least 100 cells were evaluated for each case; loss of chromosome 3 was reported 
when more than 15% of cells showed a single signal for chromosome 3. 
FISH analysis for chromosome 6 was carried out with BAC clone RP11-513I15 
located at 6p21.31 and RP11-697G4 for 6q located at 6q21 obtained from M. 
Rocchi (Resources for Molecular Cytogenetics, Bari, 
http://www.biologia.uniba.it/rmc/), as previously described by our group (Fig 9-10).13 
Briefly, BAC probes were biotin- and digoxigenin-labeled by nick translation using 
the biotin-nick and DIG-nick translation mix (Roche, Mannheim, Germany). For 
each experiment, 100ng of labeled probe were used for hybridization following 
standard procedures. Signal detection was made using Avidin-Cy3 (Amersham 
Biosciences, Little Chalfont, UK) diluted 1:100 in phosphate-buffered saline (PBS; 
Gibco-BRL, Paisley, UK) and anti-digoxigenin–fluorescein (Roche) diluted 1:200 in 
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PBS. Microscopic analyses were carried out using a fluorescent Zeiss Axioplan 
microscope (Carl Zeiss, Göttingen, Germany) with appropriate single band and 
triple band filters. At least 100 cells per sample were evaluated and a cut-of of 10% 
for chromosome 6 probes was considered. Results of hybridization with 6p (red) 
and 6q (green) probes were classified as follows: a signal pattern of 3R1G and 
4R1G was considered as +6p. 
MLPA analysis was carried out using a kit specifically designed for UM  (SALSA 
P027 (B1; MRC-Holland), as previously described (Fig 11). 14 This comprises 12 
control probes and test probes directed at 7 loci on chromosome 1, 13 loci on 
chromosome 3, 6 loci on chromosome 6, and 5 loci on chromosome 8. DNA 
extraction, DNA quality assessment and quantification, and MLPA were conducted 
as previously reported. 14 
 
RESULTS 
 
One hundred thirty-nine consecutive patients affected by posterior UM (mean age, 
63.3 ± 10.4 years; range, 36 to 82 years) were included in this study. Seventy-five 
patients were male (56.2%) and sixty-four female (43.8%). The right eye was 
affected in 71 patients (50.7%) and the left eye in 68 cases (49.3%). Ninety-seven 
melanomas were purely choroidal in location (70.3%) whereas 42 eyes were 
affected by ciliary body tumors (29.7%). Mean tumor largest basal diameter was 
12.5 ± 2.7 mm (range, 7–15 mm) and mean tumor thickness was 6 ± 2.9 mm 
(range, 3–11 mm). Mean follow-up was 54±16 months (range, 24-84 months). 
Transcleral FNAB yielded enough material for (at least) a single FISH analysis 
(monosomy 3) in 117 cases (84.2%). In the remaining 21 cases, the aspirate was 
graded as insufficient (15.8%). FNAB yielded sufficient specimens in 39 ciliary body 
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tumors (92.8%) and in 79 choroidal neoplasms (81.4%) (p=0.037). No correlation 
was found between tumor dimension (thickness and largest basal diameter) or 
tumor location (ciliary body vs choroidal location) and adequacy of FNAB (p > 0.05). 
Monosomy 3 was detected in 56 cases (47.9%) and disomy 3 in the remaining 61 
cases (52.1%). No correlation was found between chromosome 3 status and tumor 
dimensions (p> 0.05), and between monosomy 3 and tumor location (ciliary body vs 
choroidal location) (p > 0.05). Among monosomy 3 tumors, the mean percentage of 
monosomic cells in each sample was 89% ± 9.4% (range, 39–100%). Considering a 
cut-of of 15%, no clinically relevant monosomy 3 heterogeneity was detected 
separately analysing sampled material obtained by the double pass sampling 
procedure. Considering patients with monosomy 3 (N=117), thirty-one patients 
(26.5%) died during follow up. Twenty-nine of them (93.5), died due to liver 
metastatic disease, which developed 24 ± 7 months (range, 16–40 months) after 
treatment, without any evidence of extrascleral recurrence in the sampled site. Two 
patients (6.5%) died of unrelated causes. Considering the 29 patients that 
developed metastatic disease, 22 were affected by monosomy 3 UM, whereas 7 by 
a disomy 3 tumor. Univariate Cox analysis showed metastatic disease to be 
strongly associated with monosomy 3 (p=0.005). 
Chromosome 6 co-detection using FISH was performed in forty-four patients. 
Chromosome 6 normal pattern was found in 24 patients (55.6%), whereas 20 
patients were affected by a +6p tumor (45.4%). Monosomy 3 and +6p resulted 
mutually exclusive in 40 cases (90.9%), whereas the coexistence of -3 and +6p was 
found in 4 patients (9.2%). Considering this sub-group having both chromosome 3 
and 6 data, 12 patients (28.5%) developed metastatic disease. O these, 3 patients 
have both -3 and +6p (25%), and 9 patients were affected by monosomy 3 tumors 
with normal chromosome 6 (75%). No misclassification occurred in low risk patients 
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having both disomy 3 and +6p (no metastatic disease). 
MLPA was performed in twenty-four patients having also FISH result for 
chromosome 3. MLPA revealed the presence of monosomy 3 in thirteen cases 
(54%) (vs twelve cases classified as -3 by FISH) and a 3p14-q29 deletion in one 
case (4%) (classified as monosomy 3 by FISH) (Fig 11). Considering this sub-group 
of twenty-four patients having both FISH and MLPA results, nine patients (41%) 
developed metastatic disease during follow-up, including the case showing 
monosomy 3 only by MLPA. Patient with partial chromosome 3 deletion by MLPA is 
still alive without metastases. 
 
DISCUSSION 
 
Ophthalmic oncologists are among the few, if not the only, cancer-treating physician 
who do not routinely use cyto- or histologic confirmation before treating a clinically 
diagnosed malignancy.11 Therefore, intraocular FNAB is not usually used in a 
routine clinical setting to sample intraocular lesions. 11, 15 There are at least two 
reasons: a wide accepted high accuracy in non-invasive diagnosis of posterior UM 
by expert clinicians, and the claimed risk of tumor diffusion secondary to diagnostic 
invasive approaches. 11 About the former, it has been convincingly proven by the 
Collaborative Ocular Melanoma Study (COMS) for lesions whose dimension are 
thickness  >3 mm and largest basal diameter more than 10 mm. 16 But about the 
latter, there is no evidence of an increased risk of UM local diffusion following 
correctly performed FNAB. 11 Nevertheless, complications are typically under-
reported in literature and, to the best of our knowledge, no specific long-term 
studies are available on this topic. Moreover, UM shows some peculiarities 
compared to the majority of solid cancers: (i) disease related mortality is unchanged 
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during the last 100 years, despite the introduction of new conservative therapeutic 
approaches [7]; (ii) UM mortality seems completely unrelated to type and result of 
local treatment (not conclusive evidence of a life-extending benefit of local treatment 
for medium-size UM) (iii) cytogenetic profile of posterior UM is extremely simple 
(unlike of most solid tumors) and is currently considered the most important 
prognostic factor for metastatic disease. 11 These considerations give raise relevant 
questions about the biology and the natural history of UM, moving the interest of the 
clinicians from the treatment of the primary tumor to its biological behaviour. 
Cytogenetic analysis of posterior UM has contributed to the delineation of the 
pattern of genetic alterations in this tumor. 2, 5-10 Recurrent chromosomal 
abnormalities affecting chromosome 1, 3, 6 and 8 have been described and 
correlated with prognosis. 2, 5-10 Loss of chromosome 3, loss of short arm of 
chromosome 1 and gain of 8q have been associated with decreased survival, 
whereas +6p with a low metastatic risk. 2, 5-10 Because histologic material is not 
traditionally available when conservative treatment is performed, conservatively 
treated patients were excluded from any information about life prognosis. 2, 6, 11 We 
considered that moving cytogenetic prognostication from the ex-vivo to the in-vivo 
arena may represent a relevant improvement in the clinical identification of this risk 
factor in patients affected by posterior UM. Moreover, clinicians are unable to 
accurately select patients at high risk for metastasis to be included in on-going 
studies of adjuvant chemotherapy basing only on clinical UM features. 2, 6, 11 These 
considerations led us to introduce, few years ago, a simple and reliable technique to 
detect cytogenetic alterations in-vivo. 2 With this long.term study we have 
demonstrate that early complications following intraocular FNAB are rare and time-
limited. Moreover, we have never found any long-term complication, as well as local 
recurrences or extra-ocular extension due to sampling procedure. To the best of our 
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knowledge, only one suspected clinical case of extrascleral recurrence has been 
reported after diagnostic intraocular transscleral FNAB in UM patients.17 
Furthermore, compared to our approach that includes full radiation treatment of the 
entry site, no treatment was applied over the sampled area and the tumor base. 
Thus, concerns about tumor seeding due to this diagnostic procedure should be 
dispelled by our data.  The proportion of adequate biopsies for analysis was higher 
for ciliary body melanomas than for choroidal melanomas, reaching statistical 
significance. This fact may be explained by the higher technical difficulties of 
sampling more posteriorly located tumors. A transvitreal approach has recently 
been investigated for these lesions by Shields et al.18 According to this study, based 
on 140 eyes with limited follow-up, tumors located posterior to the equator (67 of 
140 eyes: 48%) and sampled via pars plana yielded sufficient material in 65 of 67 
cases (97%). Unfortunately, this study reports a high number of local complications 
(vitreous haemorrhages in 64 eyes), probably related to the direct trans-retinal 
approach to the tumor apex. 18 In the same series, a lower rate of sufficient material 
(75% vs 97%) was obtained when the tumors were sampled with 30- vs 27- gauge 
needle. Balancing needle diameter vs tumor approach needs further investigation. 18 
A 25-gauge vitrector has recently been claimed to give more material than 
transvitreal or transscleral FNAB. 19 Unfortunately, this technique is more 
aggressive and surgically demanding, and its safety is unknown. 11 Moreover, using 
the FNAB technique, a double-pass is always recommended to reduce the 
incidence of insufficient sampling. 1, 6, 11 Sampled tumors were not classified by 
cytology after FNAB, because FNAB material was fully used for cytogenetic 
analysis. FNAB adequacy, as reported by Sisley et al., seems independent of 
melanoma dimensions, as confirmed by our data. 20 FISH testing showed 
monosomy 3 in 47.9% of our cases. Previous ex vivo studies reported monosomy 3 
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in 40–65% of sampled cases. 9-20 The high percentage of monosomy 3 cells in each 
positive sample (89% ± 9.4%) shows that, when present, monosomy 3 is fully 
exposed and easily detected by FNAB sampling. The presence of heterogeneous 
distribution of monosomy 3 has been recently evaluated in some case series, with 
conflicting results. 21 However, Meir et al., using a larger pattern of laboratory 
investigations, were not able to detect tumor heterogeneity. 21 In our study no 
correlation was found between monosomy 3 and tumor dimension. Considering 
literature data, the existence of a correlation between these two parameters 
remains unclear. 2, 6, 18, 22 Our sampling technique for in-vivo cytogenetic 
prognostication of posterior UM differs from standard FNAB. 2, 6 We use partial 
scleral incision, followed by suture immediately after sampling, to avoid excessive 
pressure when penetrating the sclera (particularly relevant in small tumors). This 
manoeuvre, followed by direct application of radioactive plaque over the tumor 
base, improves the safety of tumor sampling. 11 Long-term safety of this sampling 
procedure is proven by the absence of any local extrascleral recurrence during a 
log-term follow-up. Moreover, patients’ mortality rate from liver metastasis 36 
months after treatment agrees with previously published data. 3 Our data 
demonstrate that monosomy 3 alone sometimes fail to personalize patients 
prognosis, mainly considering the false-negative results (patients without 
monosomy 3 that will develop metastatic disease). To reduce false negative results 
we have introduced the chromosome 6 co-detection, aimed exploring the second 
cytogenetic pathway of UM. 13 This double check can be performed using a second 
FISH analysis or MLPA, exploring in a single reaction different selected 
chromosomes related to UM pathway and prognosis. 13 Using chromosome 6 co-
detection by FISH we have reduced the false-negative results because, considering 
the sub-group having both chromosome 3 and 6 data, no misclassification occurred 
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in low risk patients having both disomy 3 and +6p (no metastatic disease). 
Therefore, we retain that a multichromosomal analysis should be actually preferred. 
11 Considering MLPA vs FISH analysis, MLPA revealed a single case of monosomy 
3 that FISH classified as non-monosomic. Considering that this patient developed 
metastatic disease during follow-up, we conclude that MLPA is superior to FISH in 
the cytogenetic prognostication of UM, even if the difference in specificity is 
minimal. 14 Another advantage of MLPA is that using one single reaction this test 
can explore more than a single chromosome status, allowing checking both UM 
pathways in a single reaction. 14 About the sampling amount of material for both 
FISH and MLPA, in our experience, these two techniques are in need of the same 
amount of cells. Moreover, the cost of these two analyses is similar. The second 
claimed advantage of MLPA is its ability to detect subtle structural chromosomal 
alterations compared to FISH. 14 In our study only a single case of partial 
chromosome 3 deletion was found by MLPA (3p14-q29), which was classified as 
non-monosomic by FISH. We actually do not know the prognostic value of 
chromosome 3 partial deletions, considering that only monosomy 3 is claimed to be 
prognosis-related. In this case of 3p14-q29 deletion, the patients do not developed 
metastatic disease during follow-up. Thus, relevant question are rising on the 
biological means of partial chromosome 3 deletions, as well as their prognostic 
value. Recently, Harbour et al have suggested the presence of a prognosis-related 
minimal region of deletion in UM, located in 3p21.1 and encoding BRCA1-
associated protein 1 (BAP1). 23 The absence of BAP1 involvement in our patient 
with partial chromosome 3 deletion may explain the lack of metastatic disease 
during follow-up in this case. Unfortunately, no other group has confirmed this 
finding on BAP1. Therefore, we do not precisely know if a minimal region of deletion 
with prognostic value really exists in UM (and where is located on chromosome 3). 
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Thus, we retain that partial chromosome 3 deletions should actually not be 
considered clearly as a prognosis related alteration. Therefore, there are actually no 
many advantages, in a routine clinical setting, using MLPA compared to FISH to 
check for subtle chromosomes alteration: even if we get a lot more information by 
MLPA, we are not able to interpreter the biological and prognostic means of these 
findings. 14 
Other laboratory techniques have been used to investigate monosomy 3 in UM: 
single nucleotide polymorphisms, comparative genomic hybridization array and 
microsatellite analysis are claimed to be able to detect more subtle structural 
alterations. 24-28 However, the same considerations of MLPA are applicable to these 
techniques. Moreover, FISH technique continues to be considered an appropriate 
and reliable method for UM prognostication, and it is easily available in many 
clinical laboratories. 11 
In conclusion, the use of 25-G transcleral FNAB appears a long-term safe and 
effective procedure for in-vivo cytogenetic testing of posterior UM. Combined 
analysis of both arms of UM bifurcated pathway (-3 and +6p) increase predictive 
value of FISH technique. MLPA allows obtaining more information than standard 
FISH in UM prognostication. The biological and prognostic value of partial 
chromosome 3 deletion, as well as others subtle chromosomes alterations or 
complex MLPA results, remains unclear. 
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FIGURE LEGENDS 
Fig.1: Medium-sized uveal melanoma in a left eye. 
Fig 2: Liver metastases from uveal melanoma.  
Fig 3: Bifurcated cytogenetic pathways of UM clonal evolution: one starts with the 
loss of an entire chromosome 3 and continues with gains of 8q (high risk of 
metastatic disease); the second pathway starts with gain of 6p (low-risk).29 
Fig 4: Metastases-free survival probability related to monosomy 3 
presence/absence.27 
Fig 5: Tumor trans-illumination aimed at correctly localize tumor base during 
sampling procedure. 
Fig 6: Tumor localization after trans-illumination. 
Fig.7: Tumor sampling using 25-gauge needle. 
Fig.8: Sampled material is collected on RPMI. Note the large amount of tumor 
material in this case. 
Fig 9: Fluorescence in situ hybridization analysis of tumor material sampled by fine 
needle aspiration biopsy. A case with disomy 3: each cell has two chromosomes 3 
(in red) and two chromosomes 10 (labelled in green as controls). 
Fig 10: Fluorescence in situ hybridization analysis of tumor material sampled by fine 
needle aspiration biopsy. A case with monosomy 3: each cell has two 
chromosomes 10 (labelled in green), but only one chromosome 3 (labelled in red). 
Fig 11: Uveal melanoma with a 3p14-q29 deletion: MLPA and FISH comparison. 
Note that FHIS classified this patient as monosomy 3 (centromeric probe in included 
in the region of deletion).  
 
 
	   23	  
REFERENCES 
1. Seregard S. Posterior uveal melanoma. Acta Ophthalmol Scand 1996;74:315-29. 
2. Midena E, Bonaldi L, Parrozzani R et al. In vivo detection of monosomy 3 in eyes 
with medium-sized uveal melanoma using transscleral fine needle aspiration biopsy. 
Eur J Ophthalmol 2006;16:422–425 
3. Diener-West M, Reynolds SM, Agugliaro DJ et al. Development of metastatic 
disease after enrollment in the COMS trials for treatment of choroidal melanoma: 
Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 
2005;123:1639-43. 
4. Augsburger JJ, Correa ZM, Shaikh AH. Effectiveness of treatments for metastatic 
uveal melanoma. Am J Ophthalmol 2009;148:119-27. 
5. Gambrelle J, Labialle S, Dayan G, et al. Toward monosomy 3 as the main 
prognosis factor of uveal melanoma: current cytogenetic data. J Fr Ophtalmol 
2004;27:1061-7. 
6. Midena E, Bonaldi L, Parrozzani R et al. In vivo monosomy 3 detection of posterior 
uveal melanoma: 3-year follow-up. Graefes Arch Clin Exp Ophthalmol. 
2008;246:609-14 
7. Kilic E, Naus NC, van Gils W, et al. Concurrent loss of chromosome arm 1p and 
chromosome 3 predicts a decreased disease-free survival in uveal melanoma 
patients. Invest Ophthalmol Vis Sci 2005;46:2253-7.  
8. Prescher G, Bornfeld N, Becher R. Non-random chromosomal abnormalities in 
primary uveal melanoma. J Natl Cancer Inst 1990;82:1765-9.  
9. Sisley K, Rennie IG, Cottam DW et al. Cytogenetic findings in six posterior uveal 
melanomas: involvement of chromosomes 3, 6 and 8. Genes Chromosomes 
Cancer 1990;2:205-9. 
10. Prescher G, Bornfeld N, Horsthemke B et al. Chromosomal aberrations defining 
	   24	  
uveal melanoma of poor prognosis. Lancet 1992;339:691-2. 
11. Midena E, Parrozzani R. Biopsies in Uveal Melanoma. Dev Ophthalmol. 
2012;49:81-95.  
12. Nag S, Quivey JM, Earle JD et al; American Brachytherapy Society. The American 
Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int 
J Radiat Oncol Biol Phys. 2003;56:544-55. 
13. Bonaldi L, Midena E, Tebaldi E et al. FISH analysis of chromosomes 3 and 6 on fine 
needle aspiration biopsy samples identifies distinct subgroups of uveal melanomas. 
J Canc Res Clin Onc 2008;134:1123-7. 
14. Damato B, Dopierala JA, Coupland S. Genotypic Profiling of 452 Choroidal 
Melanomas with Multiplex Ligation-Dependent Probe Amplification. Clin Cancer Res 
2010;16:6083-6092. 
15. Midena E, Segato T, Piermarocchi S et al. Fine needle aspiration biopsy in 
ophthalmology. Surv Ophthalmol 1985;29:410-22. 
16. The Collaborative Ocular Melanoma Study Group: Accuracy of diagnosis of 
choroidal melanoma in the Collaborative Ocular Melanoma Study. COMS report No 
1. Arch Ophthalmol 1990;108:1268–1273.  
17. Caminal JM, Sanz S, Carreras M et al: Epibulbar seeding at the site of a transvit- 
real fine-needle aspiration biopsy. Arch Ophthalmol 2006;124:587–589.  
18. Shields CL, Ganguly A, Materin MA et al: Chromosome 3 analysis of uveal 
melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 
140 consecutive cases: the Deborah Iverson, MD, Lectureship. Arch Ophthalmol 
2007;125:1017–1024. 
19. Sen J, Groenewald C, Hiscott PS et al: Transretinal choroidal tumor biopsy with a 
25-gauge vitrector. Ophthalmology 2006;113:1028– 1031. 
20. Sisley K, Nichols C, Parsons MA et al. Clinical applications of chromosome 
	   25	  
analysis, from fine needle aspiration biopsies, of posterior uveal melanomas. Eye 
1998;12:203–207 
21. Maat W, Jordanova ES, van Zelderen-Bhola SL, et al: The heterogeneous 
distribution of monosomy 3 in uveal melanomas: implications for prognostication 
based on fine-needle aspiration biopsies. Arch Pathol Lab Med 2007;131:91–96. 
22. Scholes AGM, Damato BE, Nunn J, et al. Monosomy 3 in uveal melanoma: 
correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis 
Sci 2003;44:1008–1011 
23. Harbour JW, Onken MD, Roberson EDO, et al. Frequent mutation of BAP1 in 
metastasizing uveal melanomas. Science. 2010;330:1410-3.  
24. Aalto Y, Eriksson L, Seregard S et al. Concomitant loss of chromosome 3 and 
whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary 
uveal melanoma. Invest Ophthalmol Vis Sci 2001;42:313–317 
25. Hughes S, Damato BE, Giddings I et al. Microarray comparative genomic hybrid- 
isation analysis of intraocular uveal melanomas identifies distinc- tive imbalances 
associated with loss of chromosome 3. Br J Cancer 2005;93:1191–1196 
26. Tschentscher F, Prescher G, Zeschnigk M et al. Identification of chromosome 3, 6, 
and 8 aberrations in uveal melanoma by microsatellite analysis in comparison to 
comparative genomic hybridization. Cancer Genet Cytogenet 2000;122:13–17 
27. Worley LA, Onken MD, Person E et al. Transcriptomic versus chromo- somal 
prognostic markers and clinical outcome in uveal melano- ma. Clin Cancer Res 
2007;13:1466–1471 
28. Onken MD, Worley LA, Person E et al. Loss of Heterozygosity of chromosome 3 
detected with single nucleotide polymorphisms is superior to monosomy 3 for 
predicting metastasis in uveal melanoma. Clin Cancer Res 2007;13:2923–2927 
29. Höglund M, Gisselsson D, Hansen GB et al. Dissecting karyotypic patterns in 
	   26	  
malignant melanomas: temporal clustering of losses and gains in melanoma 
karyotypic evolution. Int J Cancer. 2004;108:57-65. 
 
 
 
 
